All-trans Retinoic Acid, and Arsenic +/- Idarubicin
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of arsenic trioxide
(ATO) with ATRA and possibly idarubicin is effective in treating patients with
newly-diagnosed APL.